Compound Details
NOVA-T4 tablets contain Levothyroxine Sodium (CAS 55-03-8). Pharmaceutical-grade thyroid hormone support by NovaTech Sciences for metabolic balance and thyroid health.
Form
Oral tablets
Strength
50 mcg Levothyroxine Sodium T4 per tablet
Packaging
Blister pack of 10 tablets
Tablet Type
Precision-dosed T4 tablet
Usage Category
Thyroid hormone support, metabolism regulation, fat-loss support
Suitable For
Individuals with hypothyroidism or those needing regulated thyroid support during performance cycles
NOVA-T4 Tablets by NovaTech Sciences contain premium-grade Levothyroxine Sodium (CAS 55-03-8), a synthetic form of the thyroid hormone thyroxine (T4). Levothyroxine is widely recognized for its role in thyroid hormone replacement therapy and metabolic regulation. Identified globally by CAS 55-03-8, Levothyroxine Sodium ensures standardized chemical identification and pharmaceutical authenticity across international supply chains.
NovaTech Sciences manufactures Levothyroxine Sodium CAS 55-03-8 under strict pharmaceutical quality control protocols designed to ensure formulation consistency, chemical purity, and global export compliance.
Levothyroxine Sodium is a synthetic form of the naturally occurring thyroid hormone thyroxine (T4). Registered under CAS 55-03-8, Levothyroxine Sodium is used to restore normal thyroid hormone levels in individuals with thyroid hormone deficiency.
The CAS registry number 55-03-8 serves as the internationally recognized chemical identifier for Levothyroxine Sodium. This ensures compound traceability, regulatory clarity, and pharmaceutical standardization in global healthcare markets.
Levothyroxine Sodium (CAS 55-03-8) functions as a replacement for the natural thyroid hormone produced by the thyroid gland. Once administered, Levothyroxine is converted into the active hormone triiodothyronine (T3) within body tissues.
By restoring adequate hormone levels, Levothyroxine Sodium CAS 55-03-8 supports balanced metabolic activity and endocrine function.
Each batch of Levothyroxine Sodium CAS 55-03-8 undergoes analytical testing to confirm chemical identity, purity verification, and formulation consistency.
NovaTech Sciences operates as a trusted manufacturer, supplier, and exporter of pharmaceutical-grade endocrine medications for international markets. By clearly specifying CAS 55-03-8, NOVA-T4 tablets maintain chemical authenticity and regulatory transparency.
These processes ensure Levothyroxine Sodium tablets meet the strict quality expectations of pharmaceutical distributors and healthcare markets worldwide.
NovaTech Sciences prioritizes pharmaceutical precision, regulatory compliance, and product reliability. NOVA-T4 tablets containing Levothyroxine Sodium CAS 55-03-8 are manufactured using advanced pharmaceutical technologies to maintain consistent therapeutic performance.
For distributors and healthcare suppliers seeking a dependable source of Levothyroxine Sodium (CAS 55-03-8), NOVA-T4 Tablets by NovaTech Sciences offer verified compound identity, pharmaceutical manufacturing excellence, and reliable global supply. Supported by strict quality assurance systems, Levothyroxine Sodium CAS 55-03-8 remains a widely recognized thyroid hormone replacement compound associated with metabolic balance and endocrine health support.
Precautions
Contraindications
Levothyroxine Sodium T4 is a synthetic thyroid-hormone compound associated with NOVA-T4 tablets by Nova Techsciences. The company’s compound page lists Levothyroxine Sodium at 50 mcg per tablet, supplied in a blister pack of 10 tablets. Levothyroxine Sodium is identified by CAS Number 55-03-8 and represents the sodium salt of levothyroxine, a synthetic form of the natural thyroid hormone thyroxine, commonly called T4.
This compound page is intended to provide clear chemical, pharmaceutical and safety information. It should not replace approved prescribing information, thyroid-function monitoring or advice from a qualified healthcare professional.
Levothyroxine is used in authorised medical settings as thyroid-hormone replacement, particularly for hypothyroidism. After administration, part of the circulating T4 is converted in body tissues to triiodothyronine, or T3. Thyroid hormones influence metabolism, growth, development and cardiovascular function. Treatment should be individualised using clinical assessment and thyroid-function tests.
Levothyroxine tablets require precise manufacturing controls because relatively small differences in active-ingredient content may influence treatment. A dependable compound profile should be supported by raw-material identity testing, active-ingredient assay, content-uniformity analysis, dissolution testing, impurity assessment, stability studies and packaging-integrity checks.
Each batch should carry a unique number linked to its manufacturing history and laboratory-release results. Claims concerning pharmaceutical grade, purity or international compliance should only be published when supported by current documentation. For the United Kingdom, Netherlands and other European markets, Nova Techsciences should clearly state the applicable marketing-authorisation status, prescription category, responsible manufacturer and adverse-event reporting route.
Levothyroxine requires professional supervision. Excessive thyroid-hormone exposure may cause rapid heartbeat, palpitations, sweating, tremor, nervousness or unexplained weight loss. Particular caution is required in people with cardiovascular disease, long-standing hypothyroidism or untreated adrenal insufficiency. Official prescribing information states that thyroid hormones should not be used for weight reduction because excessive amounts can cause serious or life-threatening adverse effects.
Cabergoline is a dopamine D2 receptor agonist identified by CAS Number 81409-90-7. Nova Techsciences lists it as a 0.5 mg tablet. It is pharmacologically unrelated to thyroid hormones and requires separate information covering cardiovascular precautions, contraindications, interactions and professional monitoring.
Fluoxymesterone is an oral androgenic and anabolic steroid identified by CAS Number 76-43-7. Nova Techsciences presents it as a 5 mg tablet. Its compound page should independently address liver, cardiovascular, hormonal and reproductive risks, together with verified regulatory status and batch documentation.
Liothyronine Sodium T3 is an active synthetic thyroid hormone identified by CAS Number 55-06-1. Nova Techsciences lists a strength of 50 mcg per tablet. It differs from T4 in its pharmaceutical behaviour and requires separate prescribing, monitoring and safety documentation.
Oxandrolone is an anabolic-androgenic steroid identified by CAS Number 53-39-4. Nova Techsciences presents it as a 10 mg tablet. It is chemically distinct from Levothyroxine Sodium and requires separate information on legal status, contraindications, liver and cardiovascular risks and batch traceability.
Mesterolone is an orally active androgen identified by CAS Number 1424-00-6. Nova Techsciences lists it as a 25 mg tablet. Its compound information should separately cover authorised status, prostate and cardiovascular precautions, interaction checks, professional supervision and responsible risk communication.
Levothyroxine Sodium T4 should ultimately be presented through accurate CAS identification, precise strength information, transparent quality records, balanced safety guidance and clearly stated regulatory status.
Premium aromatase inhibitor tablets for estrogen suppression and effective hormone balance support.
Buy Tamoxifen Citrate (CAS 54965-24-1) by NovaTech Sciences. Premium tablets for estrogen modulation, hormone support, and targeted receptor activity.
Buy Anastrozole (CAS 120511-73-1) by NovaTech Sciences. Pharmaceutical-grade aromatase inhibitor tablets for estrogen suppression and hormone regulation.
